Perspective Therapeutics Q1 EPS Raised by Brookline Cap M

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Stock analysts at Brookline Cap M upped their Q1 2026 earnings per share estimates for Perspective Therapeutics in a report issued on Tuesday, March 17th. Brookline Cap M analyst K. Dolliver now expects that the company will earn ($0.31) per share for the quarter, up from their previous estimate of ($0.44). The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Cap M also issued estimates for Perspective Therapeutics’ Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.32) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.27) EPS.

Perspective Therapeutics (NYSEAMERICAN:CATX) last issued its earnings results on Monday, March 16th. The company reported ($0.51) earnings per share (EPS) for the quarter. Perspective Therapeutics had a negative net margin of 11,665.27% and a negative return on equity of 41.79%. The firm had revenue of $0.04 million during the quarter.

CATX has been the topic of several other reports. BTIG Research reaffirmed a “buy” rating and set a $14.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. HC Wainwright lifted their target price on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. UBS Group boosted their price target on shares of Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial set a $12.00 price objective on shares of Perspective Therapeutics in a report on Tuesday. Finally, Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have given a Buy rating to the company’s stock. According to data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and a consensus price target of $12.50.

Perspective Therapeutics Stock Performance

CATX stock opened at $4.60 on Thursday. The stock has a fifty day moving average of $4.34 and a 200-day moving average of $3.44. Perspective Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.16. The company has a current ratio of 5.17, a quick ratio of 8.66 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its stake in Perspective Therapeutics by 184.1% during the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares in the last quarter. Aigen Investment Management LP purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $28,000. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the 4th quarter worth approximately $31,000. Engineers Gate Manager LP bought a new position in Perspective Therapeutics in the 4th quarter valued at $35,000. Finally, AXQ Capital LP boosted its holdings in Perspective Therapeutics by 24.2% in the 4th quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the period. 54.66% of the stock is currently owned by institutional investors.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Several major firms raised ratings or price targets, which supports upside sentiment: B. Riley raised its price target to $13 and kept a Buy rating (large implied upside). UBS increased its target to $8 with a Buy. Wedbush reaffirmed an Outperform and a $11 target. Article Title
• Positive Sentiment: BTIG issued a Buy rating, adding to the cluster of bullish research that can attract momentum investors and buyers ahead of earnings. Article Title
• Positive Sentiment: Brookline Capital Markets (analyst K. Dolliver) raised EPS forecasts across Q1–Q4 2026 and lifted FY2026 from ($1.98) to ($1.27) — a meaningful reduction in projected losses vs their prior view. Incremental beat/less-bad guidance in analyst models tends to be supportive for the stock. Note Brookline’s FY view still implies a loss below consensus. Article Title
• Neutral Sentiment: Perspective announced a quarterly earnings release date (upcoming). Earnings will likely be the primary near-term catalyst and could swing the stock either way depending on clinical/program updates, cash burn, or guidance. Article Title
• Negative Sentiment: Royal Bank of Canada lowered expectations for CATX’s stock price, which may pressure sentiment among investors who follow bank research or use RBC’s view for risk management. Article Title

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.